Fortress Biotech, Inc.
FBIO
$3.85
$0.25897.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.23% | -6.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.92% | -13.10% | |||
| Cost of Revenue | 49.69% | -28.32% | |||
| Gross Profit | -24.10% | 49.88% | |||
| SG&A Expenses | 51.02% | 10.75% | |||
| Depreciation & Amortization | -0.09% | -68.90% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 49.16% | 3.61% | |||
| Operating Income | -63.43% | -16.84% | |||
| Income Before Tax | 52.80% | 4.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 52.80% | 6.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 92.39% | -27.84% | |||
| Net Income | 246.32% | -56.45% | |||
| EBIT | -63.43% | -16.84% | |||
| EBITDA | -67.17% | -17.53% | |||
| EPS Basic | 203.35% | -29.53% | |||
| Normalized Basic EPS | 315.57% | -127.71% | |||
| EPS Diluted | 193.61% | -29.53% | |||
| Normalized Diluted EPS | 294.21% | -127.71% | |||
| Average Basic Shares Outstanding | 1.62% | 1.68% | |||
| Average Diluted Shares Outstanding | 12.76% | 1.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||